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Introduction
In an article published in this issue of Breast Cancer
Research, Robson and colleagues present important find-
ings that show a decrease in long-term survival in breast
cancer patients who carry BRCA1 mutations. The study
also looked at ipsilateral recurrence and new primary breast
cancers, and found no difference between those with
BRCA1  mutations and those without [1]. A number of
researchers have focused their research on the mortality
associated with inherited mutations in BRCA1 and BRCA2.
Apart from mere interest in the epidemiological aspects of
breast malignancy, knowledge of the associated mortality is
important to the families of patients with breast cancer, and
to clinicians and scientists involved with improving the out-
comes of breast cancer. We are entering the era of tailored
therapies with targeted drugs such as Herceptin
(trastuzumab), and a vital starting point in assessing the
impact of interventions such as new drug therapy and
screening is the mortality associated with standard care.
Women making decisions about preventive options such as
risk reducing surgery need to have reliable information on
their chances of surviving breast cancer should it occur.
Indeed, decisions about the type of surgery for an incident
breast cancer will also depend on any difference in ipsilat-
eral recurrence and new primary breast cancers between
those opting for breast conserving treatment and those
having mastectomy. These issues have been substantially
addressed in the article by Robson and colleagues [1].
Methodological problems with BRCA1/2
mortality studies
The purest study to assess mortality in BRCA1/2 carri-
ers would be a prospective study of all incident breast
cancer in an outbred population. In order for this to
occur every woman would have had to give consent for
testing of fresh biological tissue (usually blood) for
genetic alterations. Many women do not wish to know
their genetic status even if they have breast cancer and
to counsel women adequately for the potential outcome
of genetic testing at the very time they are weighing up
different options regarding their treatment is distinctly
problematic. Although an argument could be made that
knowledge of BRCA1/2 status could alter treatment
including management of the contralateral breast, the
outcomes of the present study by Robson and col-
leagues [1] show that such a strategy may be misplaced.
Indeed any change in treatment would confound the
main aims of any prospective study.
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Abstract
There has been contradictory evidence as to whether BRCA1 associated breast cancers have a
poorer prognosis than non-BRCA1 cancers. In this issue of Breast Cancer Research Robson and
colleagues provide further evidence for poorer survival in BRCA1 carriers and show that it could be
attributed to failure to treat small node-negative grade 3 breast cancers with chemotherapy. There still
remains little evidence for a survival difference for BRCA2 related breast cancers. Although the high
contralateral breast cancer risk is confirmed by this study there is no real evidence for an increase in
ipsilateral recurrence or new primary breast cancers in mutation carriers up to the 10-year point.
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An alternative strategy would be to test samples anony-
mously, by coding them and blinding any clinician involved
in treatment of the patient to the results. This approach
has some ethical problems, as many women would wish to
know their mutation status. There is also likely to be a sub-
stantial refusal rate even to anonymous testing. This could
lead to a significant bias if for instance those with a strong
family history of breast cancers with poor outcomes were
more likely to decline testing. Even in a large prospective
study with very high ascertainment there are still the prob-
lems of accrual of follow-up time and the genetic testing
process itself. The cost of testing a large enough cohort
with a highly sensitive technique such as full sequencing
is likely to be prohibitive. As only 2-3% of breast cancers
in outbred populations are due to mutations in BRCA1 or
BRCA2 [2], as many as 2,800 women would have to be
accrued to arrive at a study with similar power to the one
by Robson and colleagues [1]. Such a study would be
likely to cost in excess of $3 million for the genetic testing
aspect alone (over $7.7 million at full Myriad Genetic
testing rates).
Flaws of previous mortality studies
The first studies to report on mortality associated with
BRCA1 actually suggested a survival advantage [3,4].
Although these studies were the best that could be
achieved at that stage, these reports should be dis-
counted as there was a substantial bias in the necessity of
having a (and more likely several) living affected individ-
ual(s) in a family in order to identify linkage to chromosome
17q in the first instance. The next phase of reports were of
studies based on mutation analysis. These studies were
still subject to bias as individuals were either ascertained
through existing proven BRCA1 families (the necessity
again for a living affected individual) [5,6,7] or some time
after diagnosis in Jewish families [8]. Interestingly the
latter article [8] shares some authors with the present
study [1] and it is likely that there is some overlap of
patients. Nonetheless the potential bias in the older study
will have been corrected by the methodologies of testing
tumour material in the present study. Whilst there were
trends to worse prognosis in BRCA1 carriers in these
studies they were not significant after correction for other
factors.
Attempts to correct for these selection biases have been
made in a cohort study of incident familial breast cancers
[9] and in prospectively ascertained breast cancers in
screened women in family history clinics [10]. These
studies convincingly showed for the first time a worse
prognosis in BRCA1 carriers in terms of survival.
However, matching to other familial breast cancer cases
may be problematic as non BRCA1/2 familial breast
cancer may even have a better prognosis than sporadic
breast cancer. A further case control study of early stage
breast cancer failed to reveal a worse prognosis [11].
Results of increased mortality for BRCA2 are also con-
flicting, but less clear than for BRCA1. They are based on
smaller numbers (total of only 70 patients), and have the
same methodological flaws [5,10,12,13].
The study by Robson and colleagues
The study reported in this issue of Breast Cancer
Research [1] circumvents most of the methodological
problems of the previous studies and expands on a previ-
ous report by some of the same authors [14]. Although
retrospective a very high proportion (496/584) of incident
cases have been tested for the three common Jewish
BRCA1/2 mutations. As these mutations account for
>90% of involvement of BRCA1/2 in the Jewish popula-
tion [15] such testing is equivalent to full gene sequencing
in an outbred population. As the testing was based on
tumour tissue, follow up was from diagnosis and there is
little likelihood of selection bias.
The study has strengthened the evidence for worse prog-
nosis in BRCA1 carriers, but shows that this survival
disadvantage largely disappears if patients receive chemo-
therapy. The results do, nonetheless, depend on only 17
BRCA1 carriers of uncertain age who were not treated
with chemotherapy. A further breakdown on age rather
than just using under/over 50 years threshold would have
been helpful. While data on grade and oestrogen receptor
(ER) status were not testable, it is likely that the worse
prognosis is associated with the known poor prognostic
factors in BRCA1 carriers: high-grade ER negativity and
postive p53 staining. Interestingly the authors have also
recently reported on the increased presence of glomeru-
loid microvascular proliferation being associated with
BRCA1 mutation carriers and poor prognosis [16]. If
these results are borne out, it may well be that previous
failure to treat small node negative BRCA1 patients with
chemotherapy accounts for much of the survival disadvan-
tage. Current treatment protocols are likely to address this
with nearly all small grade 3 node negative tumours now
receiving chemotherapy, but this might even be extended
to grade 2 tumours. Not surprisingly, there was little evi-
dence in this study for any efficacy for tamoxifen in a
largely ER-negative group of tumours.
Unfortunately, the present study adds little to the limited
information on BRCA2 with only 13 heterozygote carriers
identified (this excludes the compound heterozygote carry-
ing a BRCA1 mutation). On current evidence in some 83
BRCA2  mutation carriers prognosis does appear very
similar to sporadic breast cancer and may well reflect the
very similar tumour characteristics [17].
Ipsilateral and contralateral recurrence and
new primary breast cancer
After a median follow up of nearly 10 years the current
study has not shown an increase in ipsilateral risk in3
BRCA1 carriers, but has confirmed the known substantial
contralateral risk. This is at variance with other studies,
which show an increase in ipsilateral risk at longer follow
up [18]. While the authors correctly point out that when
considering treatment options at initial diagnosis it should
be the patient’s absolute risk of a further ipsilateral tumour
that determines decision-making, the authors’ own findings
of increased survival in the more recent patients managed
aggressively with chemotherapy mean that more women
will be surviving to develop ipsilateral disease. It should not
be forgotten that in most long-term follow-up studies of
radiotherapy at other sites, the incidence of true new
primary disease in the radiation field does not really occur
until 10–15 years after therapy. It is nonetheless reassuring
that the ipsilateral rates in BRCA1 are still substantially
less than the contralateral rates. This means that the radio-
therapy must be eliminating some of the new primary risk
by destroying pre-existing tumours, and perhaps preventing
cancers by eliminating a large proportion of breast epithe-
lial cells. The final proof in this situation will only be from
studies with in excess of 20 years follow up.
Conclusion
Robson and colleagues have provided further evidence to
help in the management of breast cancer in BRCA1 muta-
tion carriers. Whilst the population studied is limited to the
two common BRCA1 mutations in the Jewish population,
it is likely to extrapolate to other mutation carriers. It would
appear that BRCA1 mutation carriers have substantially
better survival when treated with chemotherapy, and even
small node-negative tumours should be treated. Further
evidence is needed to determine whether the type of
chemotherapy is important. Greater numbers are required
for firm evidence on prognosis related to BRCA2 breast
cancers. While there is encouraging news for BRCA1/2
carriers opting for breast conserving surgery, longer follow
up is required before a woman can reliably be told her ipsi-
lateral risk is no different than average.
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